IOVANCE BIOTHERAPEUTICS, INC. Foreign Currency Transaction Gain (Loss), before Tax
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Foreign Currency Transaction Gain (Loss), before Tax of -$437.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:ForeignCurrencyTransactionGainLossBeforeTax · last filed 2026-08-06
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-06-30 was -$3.00K, a 101.92% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2026-03-31 was -$434.00K.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-12-31 was $373.00K.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for the quarter ending 2025-09-30 was -$232.00K, a 349.46% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for fiscal 2025 was $238.00K, a 36.00% increase from fiscal 2024.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for fiscal 2024 was $175.00K.
- IOVANCE BIOTHERAPEUTICS, INC. foreign currency transaction gain (loss), before tax for fiscal 2023 was -$70.00K.
| Period end | Foreign Currency Transaction Gain (Loss), before Tax 3 month | Foreign Currency Transaction Gain (Loss), before Tax 6 month | Foreign Currency Transaction Gain (Loss), before Tax 9 month | Foreign Currency Transaction Gain (Loss), before Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$437.00K 10-Q · filed 2026-08-06 | -$64.00K derived: sum of 3 quarters · filed 2026-08-06 | -$296.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$434.00K 10-Q · filed 2026-05-07 | -$61.00K derived: sum of 2 quarters · filed 2026-05-07 | -$293.00K derived: sum of 3 quarters · filed 2026-05-07 | -$137.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $373.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $141.00K derived: sum of 2 quarters · filed 2026-02-24 | $297.00K derived: sum of 3 quarters · filed 2026-08-06 | $238.00K 10-K · filed 2026-02-24 |
| 2025-09-30 | -$232.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$76.00K derived: sum of 2 quarters · filed 2026-08-06 | -$135.00K 10-Q · filed 2025-11-06 | -$139.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $156.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $97.00K 10-Q · filed 2026-08-06 | $93.00K derived: sum of 3 quarters · filed 2026-08-06 | $186.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$59.00K 10-Q · filed 2026-05-07 | -$63.00K derived: sum of 2 quarters · filed 2026-05-07 | $30.00K derived: sum of 3 quarters · filed 2026-05-07 | $20.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $89.00K derived: sum of 2 quarters · filed 2026-02-24 | $79.00K derived: sum of 3 quarters · filed 2026-02-24 | $175.00K 10-K · filed 2026-02-24 |
| 2024-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $83.00K derived: sum of 2 quarters · filed 2025-11-06 | $179.00K 10-Q · filed 2025-11-06 | $285.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $86.00K 10-Q · filed 2025-08-07 | $192.00K derived: sum of 3 quarters · filed 2026-02-24 | -$165.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $96.00K 10-Q · filed 2025-05-08 | $202.00K derived: sum of 2 quarters · filed 2026-02-24 | -$155.00K derived: sum of 3 quarters · filed 2026-02-24 | $26.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$251.00K derived: sum of 2 quarters · filed 2026-02-24 | -$70.00K derived: sum of 3 quarters · filed 2026-02-24 | -$70.00K 10-K · filed 2026-02-24 |
| 2023-09-30 | -$357.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$176.00K derived: sum of 2 quarters · filed 2024-11-07 | -$176.00K 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $181.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $181.00K 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $0.00 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |